Figure 3. The effect of EphA2 monoclonal antibody pretreatment on semiquantitative lung injury scores (A), total bronchoalveolar fluid (BALF) cell count (B) and BALF protein concentration (C). In the lipopolysaccharide (LPS)-induced lung injury model, EphA2 antagonism with EphA2 monoclonal antibody led to improved lung injury scores, decreased BALF cell counts and decreased BALF proteins (p<0.05, except BALF protein), as compared to IgG pretreatment. Values are presented as mean±SD (n=4 per group).